Aveanna Healthcare: Q2 Earnings Report Boosts The Stock And Reinforces My Buy Rating

Aveanna Healthcare Holdings delivered strong Q2 2026 results, beating earnings and revenue estimates and significantly raising full-year EBITDA and revenue guidance. AVAH's valuation remains attractive versus peers, with the lowest forward P/E multiples and leading EBITDA margin, despite a 60% stock price gain since March. Private Duty Services drive 83% of revenues, but gross margins declined across all segments; rapid revenue growth offset margin pressure, yet this trend warrants monitoring. Debt remains a key risk, with almost $1.5 billion outstanding and high-interest expense, though leverage is improving and interest rate caps provide some protection.

Aveanna Healthcare Holdings ( AVAH ) released its Q2 2026 financial results before the market opened today. Adjusted earnings of $0.22 per share were $0.05 better than the street was expecting. GAAP earnings of $0.18 topped estimates by $0.03. The company beat on its top line with